Josh Makower

Josh Makower, M.D. has served on the board of Allay Therapeutics since January 2019 and is a special partner on NEA’s healthcare team. In addition to his role at NEA, Josh serves on the faculty of the Stanford University Medical and Engineering Schools as a professor of medicine and bioengineering and is director and co-founder of The Stanford Byers Center for Biodesign. Josh is also the founder and executive chairman of ExploraMed, a medical device incubator that has created nine companies over the past 25 years. Notable transactions from the ExploraMed portfolio include Acclarent, acquired by J&J in 2009; EndoMatrix, acquired by C.R. Bard in 1997; TransVascular, acquired by Medtronic in 2003; Nuelle, acquired by AyTu Biosciences in 2014; and Neotract, acquired by Teleflex in 2017. Ongoing ExploraMed/NEA ventures include Moximed, Willow Innovations, Revelle Aesthetics, and ExploraMed V. Josh currently serves on the boards of Eargo, Allay Therapeutics, Lungpacer, Revelle Aesthetics, Vesper Medical, Magenta Medical, DOTS Technology Corp., ExploraMed, Intrinsic Therapeutics, Moximed, SetPoint Medical, Willow and Coravin. Josh holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women’s health, aesthetics, and urology. He received an MBA from Columbia University, an M.D. from the NYU School of Medicine, a bachelor’s degree in mechanical engineering from the Massachusetts Institute of Technology and is a fellow of the American Institute of Biomedical Engineering and a member of the National Academy of Engineering.